D
Dariusz M. Kowalski
Researcher at Curie Institute
Publications - 161
Citations - 12935
Dariusz M. Kowalski is an academic researcher from Curie Institute. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 25, co-authored 129 publications receiving 7930 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.
Journal ArticleDOI
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Tibor Csőszi,Andrea Fülöp,Jerónimo Rodríguez-Cid,Jonathan Wilson,Shunichi Sugawara,Terufumi Kato,Ki Hyeong Lee,Ying Cheng,Silvia Novello,Balazs Halmos,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Dariusz M. Kowalski,Keynote Investigators +22 more
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok,Yi-Long Wu,Iveta Kudaba,Dariusz M. Kowalski,Byoung Chul Cho,Hande Turna,Gilberto de Castro,Vichien Srimuninnimit,Konstantin Laktionov,Igor Bondarenko,Igor Bondarenko,Kaoru Kubota,Gregory M. Lubiniecki,Jin Zhang,Debra Kush,Gilberto Lopes,Gonzalo Gomez Aubin,Luis Enrique Fein,Diego Kaen,Ruben Dario Kowalyszyn,Guillermo Lerzo,Gaston Martinengo,Matias Molina,Eduardo Richardet,Pablo Picon,Mirta Varela,J. J. Zarba,Sergio J Azevedo,Carlos H. Barrios,Carlos Beato,Carlos Alexandre Sydow Cerny,Pedro Rafael Martins De Marchi,Gustavo Fernandes,Fabio Franke,Helano C. Freitas,Gustavo Girotto,Valeria Lopes,Lucas Vieira dos Santos,Marcos Andre Costa,Andrea Kazumi Shimada,Oren Smaletz,Joao Paulo Holanda Soares,Ana Paula Victorino,Carlos Ferreira,Marchela Koleva,Krassimir Koynov,Rumyana Micheva,Tsvetan Deliverski,Zhasmina Milanova,Boyan Doganov,Susanna Cheng,Flavia De Angelis,Giovanna Speranza,Rosalyn A. Juergens,Doran Ksienski,David Fenton,Osvaldo Rudy Aren,Christian Caglevic,Hector Galindo,Felipe Rey,Jianhua Chang,Gongyan Chen,Xi Chen,Xuenong Ouyang,Ying Cheng,Zhenyu Ding,Mei Hou,Yun Fan,Jifeng Feng,Jianxing He,Yong He,Yi Hu,Wei Li,Xiaoqing Liu,Zhe Liu,Shun Lu,Shukui Qin,Qiyou Tang,Bu-Hai Wang,Kai Wang,Li Zhang,Xin Zhang,Jun Zhao,Jie Wang,Caicun Zhou,Jianying Zhou,Qing Zhou,Andrés F. Cardona,Ricardo Duarte,Luis Gomez Wolff,Angela Zambrano,Marcela Vallejo,Libor Havel,Vitezslav Kolek,Petr Kolman,Leona Koubkova,Lubos Petruzelka,Patrice Popelkova,Jaromir Roubec,Jaroslav Vanasek,Tomas Vlasek,Jana Jaal,Gerli Kuusk,Oscar Avendano,Hugo Castro,Karla Lopez,Mario Sandoval,Chung Man James Ho,Sing Hung Lo,Ibolya Laczó,Bela Piko,Gyula Ostoros,Keisuke Aoe,Yasuhito Fujisaka,Tomonori Hirashima,Atsushi Horiike,Yukio Hosomi,Katsuyuki Hotta,Masao Ichiki,Fumio Imamura,Yasuo Iwamoto,Kazuo Kasahara,Nobuyuki Katakami,Terufumi Kato,Shuji Murakami,Tomoya Kawaguchi,Kazuma Kishi,Takayasu Kurata,Yoshitaro Torii,Yasuharu Nakahara,Takashi Nishimura,Tatsuo Ohira,Hideo Saka,Toshiyuki Sawa,Nobuhiko Seki,Shunichi Sugawara,Kazuhisa Takahashi,Nagio Takigawa,Hiroshi Tanaka,Kazuhiko Yamada,Takuma Yokoyama,Toshihide Yokoyama,Hiroshige Yoshioka,Gunta Purkalne,Zinaida Stara,Alvydas Cesas,Saulius Cicenas,Marius Zemaitis,Soon Hin How,Chong-Kin Liam,Choo Khoon Ong,Lye Mun Tho,Oscar Arrieta Rodriguez,Carlos Hernandez Hernandez,Luis Mas,Luis Vera,Jorge Salas,Hermes Tejada,Regina Edusma-Dy,Christina Galvez,Guia Ladrera,Jerry Tan Chun Bing,Jacek Jassem,Ewa Kalinka-Warzocha,Boguslawa Karaszewska,Andrzej Kazarnowicz,Krzysztof Lesniewski Kmak,Rodryg Ramlau,António Araújo,Fernando Barata,Nuno Gil,Venceslau Hespanhol,A. Alexandru,Mircea Dediu,Nelly Cherciu,Daniel Ciurescu,Doina Ganea,Lucian Miron,Daniela Sirbu,Maria Turdean,Sergey Emelyanov,Nina Karaseva,Lyudmila Kuzina,Sergey Lazarev,Igor Dmitrievich Lifirenko,Larisa Bolotina,Oleg Lipatov,Elena Ovchinnikova,Marina Matrosova,Anna Alyasova,Artem Poltoratsky,Pavel Taranov,Oleg Zarubenkov,Graham Cohen,Lydia Dreosti,Freddy Seolwane,Jacqueline Hall,Gregory Hart,Christa Jordaan,Sayeuri Buddu,Michiel Botha,Gregory Landers,Bernardo Rappaport,Paul Ruff,Lucinda Shepherd,Waldemar Szpak,Myung-Ju Ahn,Joo Hang Kim,Per Bergstrom,Ronny Ohman,Hakan Griph,Daniel Betticher,Adrian F. Ochsenbein,Alfred Zippelius,Gee Chen Chan,Chao Hua Chiu,Te Chun Hsia,Wu Chou Su,Chih-Hsin Yang,Touch Ativitavas,Pongwut Danchaivijitr,Kasan Seetalarom,Aumkhae Sookprasert,Virote Sriuranpong,Ozden Altundag,Filiz Cay Senler,Mustafa Erman,Tuncay Göksel,Erdem Göker,Ozgur Ozyilkan,Mesut Seker,Mahmut Gumus,Fulden Yumuk,Grigory Adamchuk,Oleksandr Ivashchuk,Olga Ponomarova,Andrii Rusyn,Sergii Shevnya,Yaroslav Shparyk,Ivan Sinielnikov,Orest Andrusenko,Dmytro Trukhyn,Grygoriy Ursol,Ihor Vynnychenko,Tien Quang Nguyen,Xuan Dung Pham +245 more
TL;DR: Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations, and the benefit-to-risk profile suggests that first-line pembrology monotherapy can be extended as first line therapy for locally advanced or metastatic non-small-cell lung cancer patients with sensitising EGFR or ALK translocation.
Journal ArticleDOI
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares,M. Dvorkin,Y. Chen,Niels Reinmuth,Katsuyuki Hotta,D. Trukhin,Galina Statsenko,Maximilian Hochmair,Mustafa Ozguroglu,J.H. Ji,Oleksandr Voitko,A. Poltoratskiy,Santiago Ponce,Francesco Verderame,Libor Havel,Igor Bondarenko,Andrzej Kazarnowicz,György Losonczy,Nikolay Conev,Jon Armstrong,N. Byrne,Norah J. Shire,Haiyi Jiang,Jonathan W. Goldman,Emilio Batagelj,Ignacio Casarini,Anea Viviana Pastor,Susana Noemi Sena,J. J. Zarba,Otto C. Burghuber,Sylvia Hartl,Bernd Lamprecht,Michael Studnicka,Luis Alberto Schlittler,Fabricio Augusto Martinelli de Oliveira,Aknar Calabrich,Gustavo Girotto,Peo Dos Reis,Carlos Fausto Nino Gorini,Peo Rafael Martins De Marchi,Clarissa Serodio da Rocha Baldotto,Claudia Sette,Mauro Zukin,Assen Dudov,Rumyana Ilieva,Krassimir Koynov,Rositsa Krasteva,Ivan Tonev,Spartak Valev,Violetka Venkova,Minghong Bi,Chengshui Chen,Yuan Chen,Zhendong Chen,Jian Fang,Jifeng Feng,Zhigang Han,Jie Hu,Yi Hu,Wei Li,Zongan Liang,Zhong Lin,Rui Ma,Shenglin Ma,Kejun Nan,Yongqian Shu,Kai Wang,Mengzhao Wang,Gang Wu,Nong Yang,Zhixiong Yang,Helong Zhang,Wei Zhang,Jun Zhao,Yanqiu Zhao,Caicun Zhou,Jianying Zhou,Xiangdong Zhou,Vitezslav Kolek,Leona Koubkova,Jaromir Roubec,Jana Skrickova,Milada Zemanova,Christos Chouaid,Werner Hilgers,Hervé Lena,Denis Moro-Sibilot,Gilles Robinet,Pierre-Jean Souquet,Jürgen Alt,Helge Bischoff,Christian Grohe,E. Laack,Susanne Lang,Jens Panse,Christian Schulz,Krisztina Bogos,Eszter Csánky,Anea Fülöp,Zsolt Horváth,Judit Kósa,Ibolya Laczó,Gábor Pajkos,Zsuzsanna Papai,Zsolt Pápai Székely,Veronika Sárosi,Attila Somfay,Éva Somogyiné Ezer,Anás Telekes,Jair Bar,Maya Gottfried,Norman Isaac Heching,Alona Zer Kuch,Roberta Bartolucci,Anna Cecilia Bettini,Angelo Delmonte,Marina Chiara Garassino,Mauro Minelli,F. Roila,Shinji Atagi,Koichi Azuma,Hisatsugu Goto,Koichi Goto,Yu Hara,Hidetoshi Hayashi,Toyoaki Hida,Kenya Kanazawa,Shintaro Kanda,Young Hak Kim,Shoichi Kuyama,Tadashi Maeda,Masahiro Morise,Yasuharu Nakahara,Makoto Nishio,Naoyuki Nogami,Isamu Okamoto,Haruhiro Saito,Masahiro Shinoda,Shigeki Umemura,Tatsuya Yoshida,Niels Claessens,Robin Cornelissen,Lizza Heniks,Jeroen Hiltermann,Egbert F. Smit,Agnes Staal van den Brekel,Dariusz M. Kowalski,Slawomir Mandziuk,Robert Mróz,Marek Z. Wojtukiewicz,Tudor Ciuleanu,Doina Ganea,Anei Ungureanu,Alexander Luft,Vladimir Moiseenko,Dina Sakaeva,Alexey Smolin,Alexander Vasilyev,Lyubov Vladimirova,Igor Anasina,Jozef Chovanec,Pavol Demo,Robert Godal,Peter Kasan,Marian Stresko,Michal Urda,Eun Kyung Cho,Joo Hang Kim,Sang-We Kim,Gyeong-Won Lee,Jongmin Lee,Ki Hyeong Lee,Kyung Hee Lee,Yun Gyoo Lee,Maria Amelia Insa Molla,Manuel Domine Gomez,Juan Ignacio Delgado Mingorance,Dolores Isla Casado,Marta Lopez Brea,Margarita Majem Tarruella,Teresa Morán Bueno,Alejano Navarro Mendivil,Luis Paz-Ares Rodríguez,Santiago Ponce Aix,Maria Rosario Garcia Campelo,Gee-Chen Chang,Yen-Hsun Chen,Chao-Hua Chiu,Te Chun Hsia,Kang-Yun Lee,Chien-Te Li,Chin-Chou Wang,Yu-Feng Wei,Shang-Yin Wu,Ahmet Alacacioglu,Irfan Cicin,Ahmet Demirkazik,Mustafa Erman,Tuncay Göksel,Hryhoriy Adamchuk,Oleksii Kolesnik,Anna Kryzhanivska,Yuriv Ostapenko,Serhii Shevnia,Yaroslav Shparyk,Grygorii Ursol,Nataliia Voitko,Ihor Vynnychenko,Sunil Babu,Anne Chiang,Winston Chua,Shaker R. Dakhil,Afshin Dowlati,Basir Haque,Rodney Jamil,Jeanna Knoble,Shailena Lakhanpal,Kailhong Mi,Petros Nikolinakos,Steven Francis Powell,Helen Ross,Eric Schaefer,Jeffrey Schneider,Joseph Spahr,David R. Spigel,Joseph Stilwill,Christopher Sumey,M. Williamson +227 more
TL;DR: First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group and safety findings were consistent with the known safety profiles of all drugs received.
Journal ArticleDOI
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Thierry Jahan,Scott J. Antonia,Youssef Oulkhouir,Yolanda Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Abderrahim Oukessou,Christine Baudelet,Gérard Zalcman +20 more
TL;DR: The CheckMate 743 trial as mentioned in this paper showed that nivolumab plus ipilimumab significantly improved overall survival compared to standard-of-care chemotherapy for non-small-cell lung cancer.